Rezultati pretraživanja
  1. CCM is an effective device therapy for individuals with advanced and mildly to moderately reduced left ventricular ejection fraction who are not eligible for cardiac resynchronization therapy. --Dr. Bhatt

  2. Yet another great day double whammy teaching sessions happening in Echo and CRM! Thank you Dr Raj Sharma and for supporting these sessions

  3. Prikaži ovu nit
  4. Come hear cardiologist Dr. Scott Blois describe the signs of heart failure. He'll then provide an update on the latest treatment options. Tuesday, Feb. 18, 7 to 8 p.m. in RSVP now:

  5. Disproportionate functional Mitral Regurgitation (MR): a new therapeutic target in patients. A meaningful perspective by Dr Milton Packer on complementarity of RCTs about MR

  6. Worldwide prevalence of heart failure in 25 million, w/ 6 million in US. --Dr. Bhatt

  7. Manejo de falla cardiaca derecha aguda !

  8. session on presented by Heart Failure Service Manager to teams. Takes place every Friday. Great to hear the knowledge being shared & talk about reducing fluid retention in the

  9. prije 2 sata

    Activin type II receptor ligand inhibition resulted in preserved cardiac function, a decrease in cardiac , and improved SERCA2a levels after ischemic

  10. prije 2 sata

    Cannot wait!! Everything about this film is outstanding and it's so, so important for the whole family to understand living with . Such a valuable educational piece for everyone.

  11. On Feb 14th we premiere an extraordinary first - the video. Our film conceived, planned, & directed by exceptional young people impacted by HF, joined by some of the UK's leading specialists...

  12. prije 12 sati
  13. prije 16 sati

    Excellent slide by Prof Andrew Sindone describing the importance of pharmacotherapy in at today

  14. talking about interatrial shunt devices for at the Structural Heart Intervention and Imaging Conference. Interesting device that seems to have potential for treatment of patients with wide spectrum of phenotypes.

  15. prije 20 sati

    An impressive analysis from Daniel Goldstein, MD, of shows the prevalence and mortality of is higher than almost all types. More awareness of this devastating disease, and new treatment options like from , is needed!

  16. Dr. Civitello presented at the Heart Failure conference in Dubai on RV Dysfunction with LVAD Therapy: Evidence or Wisdom. It was great to connect with physicians from UAE and the region. Texas Heart Institute , , CHI St. Luke's Health

  17. * Decreased systolic function is a central factor in HFrEF * Current and investigational inotropic calcitropic drugs have uniformly resulted in signals of increased mortality * OM is a myotrope and a selective cardiac myosin activator that improves cardiac function.

    Prikaži ovu nit
  18. 6. velj
  19. 6. velj

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.